Sep 30, 2022 07:14 AM IST

Hot Stocks | These three stocks including Cipla, Jyothy Labs can give up to 23% return in short term

Post breakout from the rounding bottom pattern in August 2022, Jyothy Labs prices retested the neckline and have shown a bounce on upside pointing towards beginning of the trend on the upside.

Revlimid is shaping up to be a meaningfully large opportunity for India’s pharma universe: Nithya Balasubramanian

Apart from the drug used as part of the treatment for a type of blood cancer, other medicines going off-patent will boost the prospects of companies like Dr Reddy’s and Cipla, the healthcare analyst at Sanford Bernstein said.

Buy Cipla; target of Rs 1225: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1225 in its research report dated September 09, 2022.

Hot Stocks | Here's why you should bet on Cipla and Oberoi Realty, sell Tata Motors for short term

Cipla on the daily chart has formed a strong rounding base formation and is on the verge of a breakout. The F&O data, too, suggest the building of fresh long positions with the rise in price and rise in open interest.

Cipla closes in on 52-week high on getting USFDA nod for cancer drug

According to external data that Cipla provided, Revlimid (Lenalidomide) capsules had US sales of approximately $2.58 billion for the 12-month period ending June 2022

Cipla gets USFDA nod for cancer drug

The company has received the final approval from the US Food and Drug Administration (USFDA) for the product in strengths of 5 mg, 10 mg, 15 mg and 25 mg, Cipla said in a regulatory filing.

Stock Market Live: India’s Q1 GDP & impact on investors | August auto sales, Zee Ent, Cipla in focus

European markets closed lower as traders grappled with fears of higher interest rates and a looming economic downturn. India’s GDP growth surged 13.5% in April-June period driven by a favourable base effect and ongoing economic revival. We decode the numbers on the show.

Tata Motors, Cipla, Sunteck Realty And More: Top Stocks To Watch On September 01, 2022

These are the stocks that will possibly be in the spotlight during trading hours on September 01, Thursday. We explain the reasons why these stocks are buzzing before the Opening Bell and the factors that could come into play in trade. Check out this curated list of buzzing stocks from the Moneycontrol markets team and why they are in the news.

Cipla aims to double India business in five years, looks at innovation in US: CEO Umang Vohra

In an exclusive interview with CNBC-TV18, Umang Vohra said that the pharma major is looking at China, Brazil, South Africa, and Australia as key markets, apart from India

Neutral Cipla; target of Rs 950: Motilal Oswal

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 950 in its research report dated August 18, 2022.

Cipla board approves appointment of Ashish Adukia as new Global CFO

The new appointment will relieve Dinesh Jain from the additional responsibility of interim Chief Financial Officer.

Hot Stocks | Here's why you should bet on Lemon Tree Hotels, Cipla for short term

For the week, 17,500–17,650 remains a sturdy wall and until it is surpassed convincingly, tentativeness at higher levels will persist

Hot Stocks | Alkyl Amines Chemicals, Cipla and Tata Elxsi can give 17-23% return in short term, here's why

On the weekly chart of Alkyl Amines, the prices have shown a bounce on the upside. In the prior week, prices gave a breakout from the Falling Wedge pattern which is a bullish reversal pattern, said Vidnyan Sawant of GEPL Capital

Hold Cipla; target of Rs 1080: Arihant Capital

Arihant Capital recommended hold rating on Cipla with a target price of Rs 1080 in its research report dated August 01, 2022.

Buy Cipla; target of Rs 1110: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1110 in its research report dated August 01, 2022.

Cipla appoints Oyo's Vaidya as independent director

On the recommendation of the nomination and remuneration committee and subject to the approval of the shareholders at the ensuing annual general meeting, the company’s board has appointed Vaidya.

Cipla: Watch out for respiratory and Peptide pipelines

Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received

Buy Cipla; target of Rs 1135: ICICI Direct

ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1135 in its research report dated July 30, 2022.

Buy Cipla; target of Rs 1150: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated July 29, 2022.

Cipla Consolidated June 2022 Net Sales at Rs 5,375.19 crore, down 2.35% Y-o-Y

Cipla Standalone June 2022 Net Sales at Rs 3,157.13 crore, down 21.41% Y-o-Y

Hot Stocks | Here's why you should bet on Tata Motors DVR, Cipla for short term

On last Friday, Cipla finally managed to traverse through a neckline resistance of ‘Inverse Head and Shoulder’ pattern around Rs 960 on a closing basis. In addition, the positive placement of ‘RSI-Smoothened’ is likely to provide the much-needed impetus for the next leg of the rally

Cipla Health forays into 'nutritional wellness' segment, acquires Endura Mass

This acquisition is in line with Cipla's strategic imperative to augment the Company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.

Cipla Q1 PAT may dip 23.7% YoY to Rs 613.2 cr: ICICI Direct

Net Sales are expected to decrease by 1.2 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs 5,439.3 crore, according to ICICI Direct.

Cipla Q1 PAT may dip 23.2% YoY to Rs 645 cr: Prabhudas Lilladher

Net Sales are expected to increase by 2.9 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 5,665.5 crore, according to Prabhudas Lilladher.